Q-omics provides the consensus-scored ZNF521 profile across patient tissues and cancer cell-line models. ZNF521 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF521 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, ZNF521 RNA expression shows 19,019 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KIRP, and ACC as cancer lineages where ZNF521 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF521 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF521 survival associations across molecular data types. ZNF521 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (10) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF521 RNA expression–survival associations across cancer types. High ZNF521 expression shows unfavorable associations in KIRP, STAD, BLCA and ACC, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF521 RNA expression.
This table summarizes ZNF521 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRP for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF521. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF521 shows lower tumor expression in KIRP, KICH, THCA, UCEC, BRCA and LUSC. The KIRP box plot shows higher ZNF521 RNA expression in normal versus tumor tissue (log2 FC = −2.136, t-test p < 0.001).
This table shows molecular features associated with ZNF521 in patient tissues and cancer cell lines. In patient samples, ZNF521 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF521 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and CNS.
